Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andreeff

Showing results (411-420 of 504) with videos related to

Pageof 51
Sort By:
The Lancet. Haematology|September 5, 2022
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 studyAlexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour, et al.
Cancer|June 28, 2021
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapySangeetha Venugopal, Mahran Shoukier, Marina Konopleva, et al.
Nature Reviews. Cancer|October 12, 2012
Cancer stem cell definitions and terminology: the devil is in the detailsPeter Valent, Dominique Bonnet, Ruggero De Maria, et al.
Bone Marrow Transplantation|April 14, 2015
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantationMarina Konopleva, Christopher B Benton, Peter F Thall, et al.
Blood|February 13, 2009
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1Ramiro Garzon, Shujun Liu, Muller Fabbri, et al.
Blood Neoplasia|September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Blood|February 3, 2005
Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cellsBing Z Carter, Marcela Gronda, Zhiliang Wang, et al.
American Journal of Hematology|July 28, 2018
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-RChristopher B Benton, Maliha Khan, David Sallman, et al.
Molecular Cell|December 18, 2020
A Surge of DNA Damage Links Transcriptional Reprogramming and Hematopoietic Deficit in Fanconi AnemiaXi Shen, Rui Wang, Moon Jong Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2017
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid LeukemiaLina Han, Jeffrey L Jorgensen, Chris Brooks, et al.
Pageof 51

Showing results (411-420 of 504) with videos related to

Sort By:
Pageof 51
The Lancet. Haematology|September 5, 2022
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 studyAlexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour, et al.
Cancer|June 28, 2021
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapySangeetha Venugopal, Mahran Shoukier, Marina Konopleva, et al.
Nature Reviews. Cancer|October 12, 2012
Cancer stem cell definitions and terminology: the devil is in the detailsPeter Valent, Dominique Bonnet, Ruggero De Maria, et al.
Bone Marrow Transplantation|April 14, 2015
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantationMarina Konopleva, Christopher B Benton, Peter F Thall, et al.
Blood|February 13, 2009
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1Ramiro Garzon, Shujun Liu, Muller Fabbri, et al.
Blood Neoplasia|September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Blood|February 3, 2005
Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cellsBing Z Carter, Marcela Gronda, Zhiliang Wang, et al.
American Journal of Hematology|July 28, 2018
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-RChristopher B Benton, Maliha Khan, David Sallman, et al.
Molecular Cell|December 18, 2020
A Surge of DNA Damage Links Transcriptional Reprogramming and Hematopoietic Deficit in Fanconi AnemiaXi Shen, Rui Wang, Moon Jong Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2017
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid LeukemiaLina Han, Jeffrey L Jorgensen, Chris Brooks, et al.
Pageof 51